Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up Meeting Abstract
| Authors: | Guminski, A. D.; Lim, A. M. L.; Khushalani, N. I.; Schmults, C. D.; Hernandez-Aya, L. F.; Modi, B.; Dunn, L.; Hughes, B. G. M.; Chang, A. L. S.; Hauschild, A.; Migden, M. R.; Gutzmer, R.; Alam, M.; Jankovic, V.; Stankevich, E.; Booth, J.; Li, S.; Lowy, I.; Fury, M. G.; Rischin, D. |
| Abstract Title: | Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 514s |
| Language: | English |
| ACCESSION: | WOS:000487345806580 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.9526 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9526 -- Source: Wos |
